Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | G6PD | P11413 | 1/20 | 0.47 |
| ▸ | KAT6A | Q92794 | 12/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14964128 | 0.87 | MAPT (0.49) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL873113 | 0.87 | MAPT (0.53) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL29318048 | 0.87 | KDM4E (0.55) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL29186519 | 0.79 | NOTUM (0.55) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL16787410 | 0.79 | KAT6A (0.46) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL30050149 | 0.79 | NOTUM (0.55) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL6209994 | 0.79 | MAPT (0.43) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL387290 | 0.79 | MAPT (0.47) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL16115191 | 0.78 | KAT6A (0.41) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL29889724 | 0.78 | KAT6A (0.52) | ALDH1A1MAPTKDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-07-18 | — | — | US | disclosed |
| EP-4330233-A1 | PHENYL -O-QUINOLINE, QUINAZOLINE, THIENOPYRIDINE, THIENOPYRIMIDINE, PYRROLOPYRIDINE, PYRROLOPYRIMIDINE COMPOUNDS HAVING ANTICANCER ACTIVITY | Chengdu Anticancer Bioscience, Ltd. (CN) | 2024-03-06 | — | — | EP | disclosed |
| CN-117321036-A | phenyl-O-quinoline, quinazoline, thienopyridine, thienopyrimidine, pyrrolopyridine, pyrrolopyrimidine compounds having anticancer activity | 成都安泰康赛生物科技有限公司 | 2023-12-29 | — | — | CN | disclosed |
| WO-2022228549-A1 | PHENYL -O-QUINOLINE, QUINAZOLINE, THIENOPYRIDINE, THIENOPYRIMIDINE, PYRROLOPYRIDINE, PYRROLOPYRIMIDINE COMPOUNDS HAVING ANTICANCER ACTIVITY | Chengdu Anticancer Bioscience, Ltd. (CN) | 2022-11-03 | — | — | WO | disclosed |
| EP-2598469-A1 | PROCESS FOR THE PREPARATION OF 1-ARYL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTORS INHIBITORS | Esteve Química, S.A. (ES) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012013755-A1 | PROCESS FOR THE PREPARATION OF 1-ARYL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTORS INHIBITORS | Esteve Química, S.A. (ES) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239806-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, CPT1A, OAT | ALDH1A1 432/4885MAPT 433/4885KDM4E 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.